Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Stock Short Interest Report for October

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 1 shares, a drop of 99.8% from the October 15th total of 580 shares. Based on an average trading volume of 2,297 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Molecular Partners Trading Up 0.3%

MOLN stock opened at $3.10 on Wednesday. The stock has a 50-day moving average price of $3.86 and a two-hundred day moving average price of $4.15. Molecular Partners has a 12-month low of $3.09 and a 12-month high of $5.36. The company has a market cap of $125.18 million, a PE ratio of -1.85 and a beta of 1.17.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings data on Thursday, October 29th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Equities analysts forecast that Molecular Partners will post -1.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Molecular Partners in a research note on Monday, November 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways. Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.